《大行報告》摩通降平安好醫生(01833.HK)評級至「減持」 目標價大幅下調至27元
摩根大通發表研究報告指,認爲平安好醫生(01833.HK)正進入高風險階段,指出現時監管環境充滿挑戰,而公司的業務戰略改變亦涉及到執行及財務風險,與同業相比其風險回報傾向下行。 因此該行將其評級由「增持」降至「減持」,認爲在投資者將相關風險折算到股價、市場預期下降之前,其股價將未必會跑贏大市。
該行認爲,相信要等到平安好醫生新業務戰略見效時,纔會推動股價上升,基於2022年預測企業價值對業務收入倍數約2.5倍,將目標價由122元大幅削減至27元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.